News | May 13, 2021
COVAXIN phase II/III clinical trial approved for 2-18 years
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
Subscribe To Our Newsletter & Stay Updated
